Koch Institute investigators are working across disciplines to combine nanotechnology and novel drug combinations to improve patient care. Discover how the team’s Trojan horse approach sneaks across the blood brain barrier and packs a one-two punch that hits glioblastoma cancer cells while their defenses are down.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
